N-(3'-hydroxybenzyl)hydroxylamine | 89937-61-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: N-(3'-hydroxybenzyl)hydroxylamine
• 英文别名: 3-[(Hydroxyamino)methyl]phenol
• CAS: 89937-61-1
• 化学式: C₇H₉NO₂
• 分子量: 139.154
• InChiKey: ZNHITLCGQVQXAD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  52.5
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(3'-hydroxybenzyl)hydroxylamine 在 亚硝酸丁酯 、 氨 作用下， 以 乙醚 、 乙酸乙酯 为溶剂， 反应 0.67h， 生成 N-(3'-hydroxybenzyl)-N-nitrosohydroxylamine ammonium salt
  参考文献：
  名称：

  Synthesis and tyrosinase inhibitory activity of novel N-hydroxybenzyl-N-nitrosohydroxylamines

  摘要：

  Several novel N-substituted N-nitrosohydroxylamines were synthesized. They all inhibited mushroom tyrosinase, but the type of inhibition was different depending on the substituent. Some N-(mono- or dihydroxybenzyl)-N-nitrosohydroxylamines exhibited uncompetitive inhibition with respect to (L)-dopa. Among them, compound 6 was also a competitive inhibitor with respect to oxygen. This observation suggests that another interaction by the meta- or para-hydroxyl group might stabilize the binding of the inhibitor to the enzyme through the oxygen binding site. (C) 2003 Elsevier Science (USA). All rights reserved.

  DOI：

  10.1016/s0045-2068(03)00026-9
• 作为产物：
  描述：

  3-hydroxybenzaldoxime 在 盐酸 、 methyl orange 、 sodium cyanoborohydride 作用下， 以 甲醇 为溶剂， 生成 N-(3'-hydroxybenzyl)hydroxylamine
  参考文献：
  名称：

  Synthesis and tyrosinase inhibitory activity of novel N-hydroxybenzyl-N-nitrosohydroxylamines

  摘要：

  Several novel N-substituted N-nitrosohydroxylamines were synthesized. They all inhibited mushroom tyrosinase, but the type of inhibition was different depending on the substituent. Some N-(mono- or dihydroxybenzyl)-N-nitrosohydroxylamines exhibited uncompetitive inhibition with respect to (L)-dopa. Among them, compound 6 was also a competitive inhibitor with respect to oxygen. This observation suggests that another interaction by the meta- or para-hydroxyl group might stabilize the binding of the inhibitor to the enzyme through the oxygen binding site. (C) 2003 Elsevier Science (USA). All rights reserved.

  DOI：

  10.1016/s0045-2068(03)00026-9

文献信息

• NOVEL RHO KINASE INHIBITORS AND METHODS OF USE
  申请人：H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.

  公开号：US20140179689A1

  公开（公告）日：2014-06-26

  The subject invention concerns materials and methods for treating diseases and disorders associated with expression of Rho associated kinases (ROCKs). Examples of diseases and disorders contemplated within the scope of the invention include, but are not limited to, oncological disorders, cardiovascular diseases, CNS disorders, and inflammatory disorders. In one embodiment, a method of the invention comprises administering a therapeutically effective amount of one or more compounds of the present invention, or a composition comprising the compounds, to a person or animal in need of treatment. The subject invention also concerns compounds that inhibit ROCKs, and compositions that comprise the inhibitor compounds of the invention. Compounds contemplated within the scope of the invention include, but are not limited to, those compounds shown in Table 5.

  本发明涉及用于治疗与Rho相关激酶（ROCKs）表达相关的疾病和疾病的材料和方法。本发明范围内考虑的疾病和疾病的示例包括但不限于肿瘤学疾病，心血管疾病，中枢神经系统疾病和炎症性疾病。在一种实施方式中，本发明的方法包括向需要治疗的人或动物施用本发明的一种或多种化合物的治疗有效量，或含有该化合物的组合物。本发明还涉及抑制ROCKs的化合物和包含该抑制剂化合物的组合物。本发明范围内考虑的化合物包括但不限于表5中显示的那些化合物。
• Primary N-hydroxylamines
  申请人：——

  公开号：US20040110729A1

  公开（公告）日：2004-06-10

  The invention provides pharmaceutical compositions comprising primary N-hydroxylamines and related therapeutic, prophylactic, diagnostic and screening methods. The pharmaceutical compositions generally comprise a pharmaceutical composition comprising an orally administrable effective unit solid dosage of a primary N-hydroxylamine or a pharmaceutically acceptable salt thereof and substantially free of a nitrone corresponding to the hydroxylamine.

  本发明提供了由伯胺基 N-羟胺组成的药物组合物以及相关的治疗、预防、诊断和筛查方法。这些药物组合物一般包括一种药物组合物，其中含有可口服的有效单位固体剂量的伯羟胺或其药学上可接受的盐，并且基本上不含与羟胺相对应的腈酮。
• Isoxazolo[3,4-b]quinoline-3,4(1H,9H)-diones as unique, potent and selective inhibitors for Pim-1 and Pim-2 kinases: Chemistry, biological activities, and molecular modeling
  作者：Yunsong Tong、Kent D. Stewart、Sheela Thomas、Magdalena Przytulinska、Eric F. Johnson、Vered Klinghofer、Joel Leverson、Owen McCall、Niru B. Soni、Yan Luo、Nan-horng Lin、Thomas J. Sowin、Vincent L. Giranda、Thomas D. Penning

  DOI：10.1016/j.bmcl.2008.08.079

  日期：2008.10

  A series of isoxazolo[3,4-b]quinoline-3,4(1H,9H)-diones were synthesized as potent inhibitors against Pim-1 and Pim-2 kinases. The structure-activity-relationship studies started from a high-throughput screening hit and was guided by molecular modeling of inhibitors in the active site of Pim-1 kinase. Installing a hydroxyl group on the benzene ring of the core has the potential to form a key hydrogen bond interaction to the hinge region of the binding pocket and thus resulted in the most potent inhibitor, 19, with K-i values at 2.5 and 43.5 nM against Pim-1 and Pim-2, respectively. Compound 19 also exhibited an activity pro. le with a high degree of kinase selectivity. (C) 2008 Elsevier Ltd. All rights reserved.
• US6455589B1
  申请人：——

  公开号：US6455589B1

  公开（公告）日：2002-09-24
• US9616064B2
  申请人：——

  公开号：US9616064B2

  公开（公告）日：2017-04-11